MedWatch

Drejer: Sad to see Santaris go, but…

Symphogen CEO Kirsten Drejer mourns Denmark’s loss of the biotech company Santaris, but also sees some political aspects for Symphogen from Roche’s entry into Denmark.

Foto: Martin Slottemo Lyngstad

Last week’s news that Santaris Pharma had been bought by Swiss pharmaceutical giant Roche is received with both joy and sorrow by Symphogen’s chief executive, Kirsten Drejer.

“It’s positive from the point of view of Danish biotech and from our point of view. I’m certainly sad to see Santaris go, because I think it was one of the very good biotech companies we have in the country, and on that had been formed around the same time as Symphogen,” Kirsten Drejer says, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier